EUVIMEDEUVIMED entdecken
Crossref

Dysregulation of the ALDH1A3/PML–RARα axis promotes the progression of acute promyelocytic leukemia

Jiao Cai, Cheng-Hui Liang, Li-Ping Han, Hong-Ying Jiang, Jiang-Jie Duan, Fu Li, Jia Liu, Cai Liang, Lei Gao, Shi-Cang Yu

Cancer Letters · 2026

DOI: 10.1016/j.canlet.2026.218280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Jiao Cai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell and Regenerative Medicine, Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital (Southwest Hospi…. Hauptthemen laut MEDLINE: Leukemia, Promyelocytic, Acute, Aldehyde Oxidoreductases, Oncogene Proteins, Fusion. Die Arbeit nennt 70 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, National Major Science and Technology Projects of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dysfunction of the retinoic acid (RA) signaling pathway, which is mediated by the formation of the PML-RARA fusion gene, plays a central role in the pathogenesis of acute promyelocytic leukemia (APL). The activation of this pathway depends on the binding of the ligand RA to RA receptors (RARs). Members of aldehyde dehydrogenase (ALDH) family are key enzymes responsible for the biosynthesis of endogenous RA and are highly enriched in various cancer stem cell subpopulations; however, their specific contributions to APL pathogenesis remain poorly understood. In this study, we demonstrate that the expression of aldehyde dehydrogenase family member 1A3 (ALDH1A3) is negatively correlated with APL progression. Through DNA pull-down assays, liquid chromatography-tandem mass spectrometry (LC‒MS/MS) analysis, chromatin immunoprecipitation (ChIP), dual-luciferase reporter assays and electrophoretic mobility shift assay (EMSA), we show that ALDH1A3 cooperates with the transcription factor Myc-associated zinc finger protein (MAZ) to transcriptionally repress PML-RARα expression. Furthermore, EMSA and methylated DNA immunoprecipitation (MeDIP) analyses reveal that PML-RARα increases methylation of the ALDH1A3 promoter, thereby suppressing its expression in APL patients. This reciprocal inhibitory relationship is correlated with clinical remission in APL. Integrated RNA sequencing (RNA-seq) and Assay for Transposase-Accessible Chromatin with high-throughput sequencing (ATAC-seq) analyses indicate that ALDH1A3 overexpression is associated with increased chromatin accessibility and the upregulation of genes involved in cellular differentiation. Notably, demethylation therapy induced sustained complete remission in patients with refractory and recurrent APL during experimental treatment. Our findings underscore the critical role of ALDH1A3 in leukemogenesis and highlight its potential as a therapeutic target in APL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Promyelocytic, AcuteAldehyde OxidoreductasesOncogene Proteins, FusionHumansDisease ProgressionSignal TransductionTretinoinCell Line, TumorDNA MethylationGene Expression Regulation, NeoplasticPromoter Regions, GeneticTranscription Factors

Stichwörter der Autor:innen

Acute promyelocytic leukemia (APL)Aldehyde dehydrogenaseDemethylation therapyDifferentiationRetinoic acid

Substanzen

promyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinAldehyde Oxidoreductasesaldehyde dehydrogenase (NAD(P)+)Oncogene Proteins, FusionTretinoinTranscription Factors

Autor:innen und Institutionen

  • Department of Stem Cell and Regenerative Medicine, Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, 400038, China; Department…
  • Department of Stem Cell and Regenerative Medicine, Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, 400038, China; Internation…
  • Department of Hematology, The Second Affiliated Hospital (Xinqiao Hospital) of Army Medical University, Chongqing, 400037, China.
  • Institute of Pathology and Southwest Cancer Center, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, 400038, China.
  • Department of Hematology, The Second Affiliated Hospital (Xinqiao Hospital) of Army Medical University, Chongqing, 400037, China. Electronic address: gaolei@tmmu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • National Major Science and Technology Projects of China

Zitieren

APA

Cai, J., Liang, C. H., Han, L. P., Jiang, H. Y., Duan, J. J., Li, F., Liu, J., Liang, C., Gao, L., & Yu, S. C. (2026). Dysregulation of the ALDH1A3/PML–RARα axis promotes the progression of acute promyelocytic leukemia. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218280

Vancouver

Cai J, Liang CH, Han LP, Jiang HY, Duan JJ, Li F, et al. Dysregulation of the ALDH1A3/PML–RARα axis promotes the progression of acute promyelocytic leukemia. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218280

BibTeX
@article{Cai2026,
  author = {Cai, Jiao and Liang, Cheng-Hui and Han, Li-Ping and Jiang, Hong-Ying and Duan, Jiang-Jie and Li, Fu and Liu, Jia and Liang, Cai and Gao, Lei and Yu, Shi-Cang},
  title = {Dysregulation of the ALDH1A3/PML–RARα axis promotes the progression of acute promyelocytic leukemia},
  journal = {Cancer Letters},
  year = {2026},
  doi = {10.1016/j.canlet.2026.218280}
}
Kostenlos starten →